| Bioactivity | CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy [1],with an IC50 is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study[2]. |
| Invitro | CC214-1 (0, 0.1, 1, 2, 5, 10 μM, 8 h; 2 μM, 24 h) 与 rapamycin (HY-10219) 协同作用，抑制 mTORC1 信号传导和肿瘤细胞增殖[1]。CC214-1 (2 μM, 24 h) 介导因 EGFRvIII 表达和 PTEN 缺失而导致胶质母细胞瘤细胞生长停滞的敏感性[1]。CC214-1 (5 μM, 0-48 h) 将 LC3B-I 大量脂化为 LC3B-II 亚型，并诱导 GBM39 细胞自噬[1]。CC214-1 对 mTOR 的 IC50 为 0.002 μM[2]。CC214-1 (0-10 μM, 4days) 可有效抑制 T 细胞活化和 T 细胞活化标记物的表达[3]。 Western Blot Analysis[1] Cell Line: |
| Name | CC214-1 |
| CAS | 1021920-32-0 |
| Formula | C20H21N7O2 |
| Molar Mass | 391.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gini B, et al. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15;19(20):5722-32. [2]. Mortensen DS, et al. Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1588-91. [3]. Herrero-Sánchez MC, et al. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control. Br J Haematol. 2016 Jun;173(5):754-68. |